Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Pharmaceutical composition and its application in preparation of medicine for treating type II diabetes

A composition and technology for diabetes, applied in drug combinations, metabolic diseases, pharmaceutical formulations, etc., can solve the problems of islet β cell failure, increase the dosage, and complications, so as to reduce kidney function and structural damage, reduce Side effects, the effect of reducing side effects

Inactive Publication Date: 2007-09-05
TIANJIN INSTITUTE OF PHARMA RESEARCH
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0004] Although gliquidone has made significant progress compared with the first-generation sulfonylurea drugs, with the prolongation of medication time, the sensitivity of the islet β cell membrane receptors to it decreases, drug resistance will develop, and it is easy to cause insulin overdose. islet β-cell failure, resulting in secondary failure
At this time, it is necessary to increase the dosage or switch to other hypoglycemic drugs, and increasing the dosage often leads to the increase of side effects and the occurrence or aggravation of complications

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0047] A clinical comparative test between the combination product and gliquidone alone for the treatment of diabetes:

[0048] 1. The criteria for selection of patients are as follows: All diabetic patients meet the 1997 ADA / 1985 WHO diabetes diagnostic criteria, and 18 diabetic nephropathy (DN) patients are selected to match the rate of urinary protein, renal function and the development of renal function damage within 1 year. There was no significant difference between the two groups of patients in gender (male and female), age, course of diabetes, urine protein, urea nitrogen (BUN) and glycosylated hemoglobin (HbAlc) statistical test (P>0.05) (see table 1).

[0049] Group

example

Number

Age

Course of diabetes

(year)

Urine protein (g / L)

BUN

(mmol / L)

HbAlc(%)

Control

Group

8

54±

6.7

10.3±7.1

6.2±2.5

9.5±0.7

6.5±1.2

Treatment

Group

10

57± ...

Embodiment 2

[0072] Preparation of tablets:

[0073] A pharmaceutical composition containing 15g of gliquidone, 1058g of taurine sodium (equivalent to 900g of taurine), 100g of compressible starch, 25g of dextrin, 5g of microcrystalline cellulose, 2.5g of magnesium stearate, Mix uniformly, granulate with 40% ethanol, press tablets to make 1000 tablets, and coat them with film.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates a medicinal composition containing Gliquidone, taurine and its medicinal salts, and the use of the composition in preparing medicament for the treatment of diabetes, the treatment and / or prevention of renal disease complication related to type II diabetes. The composition comprises Gliquidone 10-180mg, taurine and its medicinal salts 0.5-10g, and pharmaceutically acceptable carrying agents.

Description

Technical field [0001] The present invention relates to a pharmaceutical composition for the treatment of diabetes, more specifically, a pharmaceutical composition containing gliquidone and taurine, and the composition is prepared for the treatment of II diabetes, treatment and / or prevention Application of combined medicine for nephropathy complications related to type II diabetes. Background technique [0002] Type II diabetes is due to genetic defects and a variety of acquired environmental factors that lead to insulin secretion defects and reduced insulin biological effects, which in turn causes a group of metabolic diseases characterized by hyperglycemia. Diabetes is the most harmful to human health due to various chronic complications based on arteriosclerosis and microvascular disease, such as diabetic nephropathy, diabetic heart disease, diabetic acral gangrene, diabetic cerebrovascular disease, and diabetic retinopathy And neuropathy, etc. Therefore, it often brings great...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K31/4704A61K31/185A61P3/10
Inventor 王春龙刘衡汤立达
Owner TIANJIN INSTITUTE OF PHARMA RESEARCH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com